key: cord-0854268-8ywh5ldb
authors: Smit, Jasper M.; Lopez Matta, Jorge E.; Vink, Roel; Müller, Marcella C.A.; Choi, Kee F.; van Baarle, Frank E.H.P.; Vlaar, Alexander P.J.; Klok, Frederikus A.; Huisman, Menno V.; Elzo Kraemer, Carlos V.; Girbes, Armand R.J.; Van Westerloo, David J.; Tuinman, Pieter R.
title: Coronavirus disease 2019 is associated with catheter-related thrombosis in critically ill patients: a multicenter case-control study
date: 2021-01-26
journal: Thromb Res
DOI: 10.1016/j.thromres.2021.01.013
sha: a36787bbd806bf1ac00cfbd5a98683be83801e2b
doc_id: 854268
cord_uid: 8ywh5ldb

• This is a multicenter case-control study conducted at four intensive care units; • COVID-19 was highly associated with catheter-related thrombosis; • The strong association seems to confirm the suggestion of an overall hypercoagulable state.

Dear Editor, Since its emergence in December 2019, the coronavirus disease 2019 (COVID-19) epidemic rapidly progressed into a pandemic. A noticeable observation in critically ill patients affected by COVID-19 pneumonia is the high incidence of thrombotic complications, especially that of pulmonary embolism. 1 A possible explanation for the hypercoagulable state is an overproduction of early response proinflammatory cytokines, causing activation of coagulation pathways. 2 Available evidence suggests that the coagulopathy associated with COVID-19 is a combination of low grade disseminated intravascular coagulation and localised thrombotic microangiopathy. 3, 4 These findings prompted multiple ICUs in the Netherlands to increase thromboprophylaxis dosage. However, the exact pathophysiology of COVID-19 associated hypercoagulability remains unclear and as increased thrombosis prophylaxis may not prevent pulmonary immunothrombosis, better knowledge of COVID-19 associated hypercoagulability is warranted. 5 Importantly, the majority of patients admitted to the intensive care unit (ICU) receive a central venous catheter (CVC) of which a considerable proportion develops catheter-related thrombosis (CRT). This is considered a serious complication as it may cause pulmonary embolism, increases the risk of infections, can cause catheter dysfunction or long-term central venous stenosis, and is associated with considerable healthcare costs. 6, 7 When considering COVID-19 coagulopathy to cause an overall hypercoagulable state rather than mainly a local pro-thrombotic state in the pulmonary circulation, COVID-19 is presumably also associated with CRT in critically ill patients with an indwelling CVC. In this multicenter case-control study we set out to investigate the association of COVID-19 with CRT, under the hypothesis that COVID-19 predisposes to CRT in critically ill patients.

J o u r n a l P r e -p r o o f Journal Pre-proof

This was a multicenter case-control study conducted at the ICUs of Amsterdam UMC, location VUmc and AMC, Leiden UMC, and Tergooi hospital, Hilversum, in The Netherlands; three tertiary centers and one secondary center. All ultrasound data was collected during routine care by the treating physicians and in compliance to COVID-19 hospital regulations. The study was approved and the necessity for informed consent was waived by the institutional review boards, and an opt-out procedure was used. STROBE-guidelines were followed. 8 

The study population consisted of adult (≥18 years) patients admitted to the ICU of the participating hospitals Moreover, as cumulative incidence of CRT increases until CVC removal, another predefined confounder was catheter indwelling-time.

A sample size of 56 was calculated by using a power of 0.80 and an α-risk of 0.05. Expected prevalence of CRT (cases) was 30%. 9 We expected 80% of all cases and 40% of the controls to be admitted because of COVID-19 pneumonia. 1 To account for data loss and confounders we aimed to include around 80 patients.

To assess distribution, histograms and Q-Q plots were evaluated. Normally distributed data are expressed as mean ± standard deviation (±SD (Figure 1b) . In multivariate analysis, the adjusted OR for CRT, given standard versus (Figure 1c) .

The main finding of this multicenter case-control study is that COVID-19 indeed predisposes to CRT in critically ill patients. These results are in line with previous research investigating thrombotic complications in critically ill patients. 1 The strong association of COVID-19 with CRT seems to confirm the suggestion of an overall hypercoagulable state, but, due to study design, causation cannot be inferred. It also underlines the fact that explanatory bonds between the COVID-19 induced-immune response and hypercoagulability are yet to be completely elucidated. A recent autopsy study showed extensive immunothrombosis over a wide pulmonary (micro)vascular territory, suggesting local pulmonary vascular endotheliopathy as a potential cause for the high incidence of pulmonary embolism, whereas the association of COVID-19 with CRT and other deep venous thrombosis suggests a more diffuse pro-thrombotic state, thought to be caused by a profound inflammatory state during acute lung injury. 4, 10 Interestingly, in line with the suggestion of a diffuse pro-thrombotic state, higher than standard The strength of our study is its multicenter and case-control design. However, because of its design, relevance of CRT for prognosis of outcome could not be assessed. Moreover, we reported large confidence intervals as CRT occurrence was low in an absolute sense. One or two additional cases of CRT could have influenced the ORs. Even so, as we found higher odds for CRT in COVID-19 patients, despite higher intensity anticoagulation, we think this will not significantly affect the validity of our conclusion.

In conclusion, COVID-19 showed to be highly associated with CRT in critically ill patients. 

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

COVID-19 cytokine storm: the interplay between inflammation and coagulation

Coagulation abnormalities and thrombosis in patients with COVID-19

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism: A different phenotype of thrombotic disease?

Upper extremity deep venous thrombosis

Pulmonary embolism from upper extremity deep vein thrombosis and the role of superior vena cava filters: a review of the literature

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

Jasper M. Smit takes responsibility for the content of the manuscript, including the data and analysis.

JS, FK, MH and PT were responsible for the conception and design of the study. JS, JM, RV, MM, KFC, FB, AV, CK, DW and PT were responsible for acquisition of the data and construction of the database. JS, FK, MH and PT were responsible for the data analysis. JS and PT were responsible for drafting the manuscript and all authors provided critical revisions for it. All authors read and approved the final manuscript and ensured that questions regarding the accuracy or integrity of any part of the work were investigated and resolved.

Data is available from the corresponding author upon reasonable request.

Approval was given by the local ethics committee (METc VUmc). Necessity for informed consent was waived and an opt-out procedure was used for data collection.